一分钟看懂
这是一项关于晚期实体瘤的I 期研究，登记的药物或干预包括HG381，当前状态为招募中。登记地点显示中国成都有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
HG381 · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- HitGen Inc. · 成都
公开的入选条件
- * Capable of giving signed informed consent.
- * Life expectancy of at least 3 months.
- * Histological or cytological documentation of an advanced solid tumor，subjects with advanced/recurrent solid tumors, who have progressed on, be intolerant of, or ineligible for, all available therapies for which clinical benefit has been established.
- * Measurable disease per RECIST version 1.1, there is at least one measurable lesion during the screening period.
- * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.
- * Adequate organ function : Hematologic system: Hemoglobin ≥9 g/dL, Absolute neutrophil count \[ANC\] ≥1.5x10\^9/L, Platelets ≥100x10\^9/L, INR ≤ 1.5 and APTT ≤1.5 x ULN; Hepatic system: Total bilirubin ≤1.5 x ULN, ALT and AST ≤ 2.5 x ULN; Renal system: serum
- * Subjects with fertility must agree to take medically approved effective contraceptive measures during the entire trial period and at least 3 months after the last medication.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04998422；登记信息更新于 2026-09-17。